Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCTHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 12.75 -0.12%
ARCT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $362.82M
- EPS (TTM)
- -$3.33
- Dividend yield
- None
- 52-week range
- 5.50 – 24.17
- Day range
- 12.59 – 13.40
- Volume / Avg
- 517.07K / 945.24K
- Beta
- —
- Shares outstanding
- 28.42M
52-week range
ARCT stock today
Arcturus Therapeutics (ARCT) closed at $12.77 on Oct 7, down 1.81% (-$0.235), versus the S&P 500's 0.22% decline. At this level, ARCT sits in the middle of its 52-week range of $5.50 to $24.17: 47.2% below the high, set on Oct 21, 2025 and 132.1% above the low. ARCT is up 108.2% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 37.6%.
Arcturus Therapeutics has posted a net loss over the last twelve months (EPS of -$3.33), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Arcturus Therapeutics
Company profileArcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Joseph E. Payne M.Sc.
- Headquarters
- San Diego, CA
- Employees
- 106
- IPO year
- 2013
- Website
- arcturusrx.com
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$23.20+81.75%
- Strong buy 1
- Buy 10
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Arcturus Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TTRXTurn Therapeutics Inc. | 12.10 | +3.95% | $367.45M | vs ARCT |
| IRDOpus Genetics Inc. | 4.41 | +0.68% | $366.89M | vs ARCT |
| GALTGalectin Therapeutics Inc. | 3.62 | -3.72% | $365.08M | vs ARCT |
| FENCFennec Pharmaceuticals Inc. | 10.36 | +0.10% | $363.30M | vs ARCT |
| ENTAEnanta Pharmaceuticals Inc. | 12.37 | +1.64% | $360.28M | vs ARCT |
| KYTXKyverna Therapeutics Inc. | 6.17 | +0.16% | $381.57M | vs ARCT |
| CCCCC4 Therapeutics Inc. | 2.82 | -2.08% | $346.93M | vs ARCT |
| RLMDRelmada Therapeutics Inc. | 3.25 | -0.91% | $346.68M | vs ARCT |
Indexes, lists and sector
Appears in lists
Arcturus Therapeutics stock FAQ
What is Arcturus Therapeutics's stock price today?
ARCT last traded at $12.77 as of Oct 7, 4:00 PM EDT, down 1.81% on the day. Prices are delayed at least 15 minutes.
Does Arcturus Therapeutics pay a dividend?
No. Arcturus Therapeutics does not currently pay a regular cash dividend.
Who is Arcturus Therapeutics's CEO?
Mr. Joseph E. Payne M.Sc. is the chief executive officer of Arcturus Therapeutics Holdings Inc., which has about 106 employees.
Has ARCT ever split its stock?
Yes. The most recent ARCT stock split was a 1-for-7 split on Nov 16, 2017.
What is the ARCT 52-week high?
The 52-week high for ARCT is $24.17 and the 52-week low is $5.50. The stock is currently 47.2% below its high.